Table 1.
No. of isolates and cumulative % inhibited at aztreonam/avibactam MIC (mg/L) of: | MIC50 | MIC90 | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Organism group (n) | ≤0.03 | 0.06 | 0.12 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | >16 | ||
CRE (1098) | 74 | 118 | 243 | 394 | 189 | 44 | 23 | 8 | 1 | 1 | 3 | 0.25 | 0.5 |
6.7 | 17.5 | 39.6 | 75.5 | 92.7 | 96.7 | 98.8 | 99.5 | 99.6 | 99.7 | 100.0 | |||
KPC producers (473) | 14 | 50 | 111 | 200 | 78 | 16 | 3 | 0 | 0 | 1 | 0.25 | 0.5 | |
3.0 | 13.5 | 37.0 | 79.3 | 95.8 | 99.2 | 99.8 | 99.8 | 99.8 | 100.0 | ||||
MBL producers (347) | 59 | 59 | 86 | 88 | 32 | 12 | 7 | 4 | 0.12 | 0.5 | |||
17.0 | 34.0 | 58.8 | 84.1 | 93.4 | 96.8 | 98.8 | 100.0 | ||||||
OXA-48-like producers (205) | 2 | 12 | 43 | 85 | 52 | 7 | 1 | 2 | 1 | 0.25 | 0.5 | ||
1.0 | 6.8 | 27.8 | 69.3 | 94.6 | 98.0 | 98.5 | 99.5 | 100.0 | |||||
≥2 carbapenemases (57) | 3 | 5 | 13 | 23 | 10 | 1 | 0 | 2 | 0.25 | 0.5 | |||
5.3 | 14.0 | 36.8 | 77.2 | 94.7 | 96.5 | 96.5 | 100.0 | ||||||
No carbapenemase (126) | 1 | 1 | 15 | 42 | 38 | 10 | 12 | 4 | 0 | 0 | 3 | 0.5 | 2 |
0.8 | 1.6 | 13.5 | 46.8 | 77.0 | 84.9 | 94.4 | 97.6 | 97.6 | 97.6 | 100.0 | |||
CZA-R (349) | 53 | 59 | 86 | 91 | 33 | 12 | 7 | 4 | 0 | 1 | 3 | 0.12 | 0.5 |
15.2 | 32.1 | 56.7 | 82.8 | 92.3 | 95.7 | 97.7 | 98.9 | 98.9 | 99.1 | 100.0 | |||
Colistin-R (292) | 17 | 12 | 61 | 124 | 63 | 11 | 2 | 1 | 0 | 1 | 0.25 | 0.5 | |
5.8 | 9.9 | 30.8 | 73.3 | 94.9 | 98.6 | 99.3 | 99.7 | 99.7 | 100.0 | ||||
Tigecycline-NS (515)a | 27 | 34 | 116 | 202 | 101 | 27 | 5 | 1 | 0 | 0 | 2 | 0.25 | 0.5 |
5.2 | 11.8 | 34.4 | 73.6 | 93.2 | 98.4 | 99.4 | 99.6 | 99.6 | 99.6 | 100.0 |
CZA, ceftazidime/avibactam; R, resistant; NS, non-susceptible.
Isolates with tigecycline MIC values >0.5 mg/L, which is the susceptible breakpoint published by EUCAST for E. coli and C. koseri.